GlaxoSmithKline plc (LON:GSK) Responds To FDA

tdp2664
E money daily
GlaxoSmithKline plc (LON:GSK) has submitted a response to the FDA for its new Drug Application for Ezogabine. Flash Player 9 or higher is required to view the chart Click here to download Flash Player now View the full GSK chart at Wikinvest GlaxoSmithKline plc (LON:GSK) Responds To FDA The pharmaceutical company GlaxoSmithKline plc (LON:GSK) and Valenat Pharma announced that they have submitted more information to the US Food and Drug Administration's request about the anti-epileptic drug Ezogabine. The FDA had rejected the ezogabine citing non clinical reasons, and asked the companies to give complete details about the drug. GlaxoSmithKline plc (LON:GSK) received the Complete Response Letter from the FDA in November last year. Ezogabine is an anti-epileptic drug for the adjunctive treatment of adults who are using other epilepsy drugs. GlaxoSmithKline plc (LON:GSK) stocks stood at 1242 at the end of the last trading session. Price History Last Price: 1242 52 Week Range: 750.00- 1,324.00 Last Vol: 1792613 3 Month Vol: 101039000